Investors in Skye Bioscience, Inc. are being urged to assess their options following a class action lawsuit related to the company’s lead drug candidate, nimacimab. The legal action, filed by Robbins LLP, aims to represent all stockholders who purchased or acquired Skye securities during the period from November 4, 2024, to October 3, 2025.
The lawsuit alleges that Skye misled investors about the efficacy and prospects of nimacimab, which is intended to treat obesity and metabolic diseases. According to the complaint, the company failed to disclose that nimacimab was less effective than previously claimed, leading to inflated expectations regarding its clinical, regulatory, and commercial potential.
On October 6, 2025, Skye released topline data from its Phase 2a CBeyondTM proof-of-concept study of nimacimab. The announcement revealed that the drug did not meet its primary endpoint of weight loss compared to a placebo. Furthermore, preliminary analyses indicated that the drug exposure was lower than anticipated, suggesting that higher dosing may be necessary for the treatment to be effective. Following this news, Skye’s stock price plummeted by $2.85 per share, a drastic 60% decline, closing at $1.90.
Shareholders interested in participating in the class action must file their documentation with the court by January 16, 2026. Those wishing to serve as lead plaintiffs will represent the interests of the class in the litigation. It is important to note that participation is not required to be eligible for a potential recovery; shareholders can remain absent class members if they choose.
Robbins LLP, a firm specializing in shareholder rights litigation since 2002, emphasizes that all representation in this case is based on a contingency fee structure, meaning shareholders will incur no upfront costs or expenses. Interested parties can find more information on the firm’s website or contact attorney Aaron Dumas, Jr. directly at (800) 350-6003.
For those seeking updates on the progress of the class action or notifications regarding potential settlements involving Skye Bioscience, signing up for Stock Watch is recommended. This service provides alerts when corporate executives engage in wrongdoing, ensuring shareholders stay informed about matters that could impact their investments.
As the situation develops, shareholders of Skye Bioscience are encouraged to carefully consider their options in light of the ongoing legal proceedings.
